NASDAQ:LIFE - aTyr Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.5515 -0.06 (-9.81 %) (As of 11/13/2018 04:00 PM ET)Previous Close$0.61Today's Range$0.55 - $0.631452-Week Range$0.55 - $4.35Volume1.19 million shsAverage Volume470,121 shsMarket Capitalization$18.83 millionP/E Ratio-0.29Dividend YieldN/ABeta2.88 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California. Receive LIFE News and Ratings via Email Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:LIFE Previous Symbol CUSIP53217V10 Webwww.atyrpharma.com Phone858-731-8389 Debt Debt-to-Equity Ratio0.26 Current Ratio5.96 Quick Ratio5.96 Price-To-Earnings Trailing P/E Ratio-0.29 Forward P/E Ratio-0.43 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$2.16 per share Price / Book0.26 Profitability EPS (Most Recent Fiscal Year)($1.87) Net Income$-48,200,000.00 Net MarginsN/A Return on Equity-74.02% Return on Assets-52.93% Miscellaneous Employees65 Outstanding Shares29,860,000Market Cap$18.83 million OptionableOptionable aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions What is aTyr Pharma's stock symbol? aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE." How were aTyr Pharma's earnings last quarter? aTyr Pharma Inc (NASDAQ:LIFE) posted its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. View aTyr Pharma's Earnings History. When is aTyr Pharma's next earnings date? aTyr Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, November 13th 2018. View Earnings Estimates for aTyr Pharma. What price target have analysts set for LIFE? 4 brokers have issued 1-year price targets for aTyr Pharma's stock. Their predictions range from $0.75 to $1.80. On average, they expect aTyr Pharma's stock price to reach $1.1833 in the next twelve months. This suggests a possible upside of 114.6% from the stock's current price. View Analyst Price Targets for aTyr Pharma. What is the consensus analysts' recommendation for aTyr Pharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma. Has aTyr Pharma been receiving favorable news coverage? News articles about LIFE stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. aTyr Pharma earned a news impact score of 0.7 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. Who are some of aTyr Pharma's key competitors? Some companies that are related to aTyr Pharma include Brainstorm Cell Therapeutics (BCLI), Oncobiologics (ONS), Entera Bio (ENTX), Genocea Biosciences (GNCA), Curis (CRIS), TRACON Pharmaceuticals (TCON), BIONDVAX PHARMA/S (BVXV), Proteon Therapeutics (PRTO), Vical (VICL), CytRx (CYTR), Arsanis (ASNS), Vaxart (VXRT), Genetic Technologies (GENE), Mymetics (MYMX) and TrovaGene (TROV). Who are aTyr Pharma's key executives? aTyr Pharma's management team includes the folowing people: Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 46)Dr. David J. King, Chief Scientific Officer (Age 59)Dr. John D. Mendlein, Strategic Advisor & Director (Age 58)Dr. Sanuj K. Ravindran, Bus. Advisor (Age 46)Xiang-Lei Yang Ph.D., Founder When did aTyr Pharma IPO? (LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers. Who are aTyr Pharma's major shareholders? aTyr Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.50%), Renaissance Technologies LLC (3.71%) and BlackRock Inc. (0.69%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Ecor1 Capital Fund Qualified,, Jill Marie Broadfoot, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma. Which institutional investors are selling aTyr Pharma stock? LIFE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and BlackRock Inc.. Company insiders that have sold aTyr Pharma company stock in the last year include Ashraf Amanullah and Ecor1 Capital Fund Qualified,. View Insider Buying and Selling for aTyr Pharma. Which institutional investors are buying aTyr Pharma stock? LIFE stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Jill Marie Broadfoot, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma. How do I buy shares of aTyr Pharma? Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is aTyr Pharma's stock price today? One share of LIFE stock can currently be purchased for approximately $0.5515. How big of a company is aTyr Pharma? aTyr Pharma has a market capitalization of $18.83 million. The biotechnology company earns $-48,200,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. aTyr Pharma employs 65 workers across the globe. What is aTyr Pharma's official website? The official website for aTyr Pharma is http://www.atyrpharma.com. How can I contact aTyr Pharma? aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected] MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 316 (Vote Outperform)Underperform Votes: 385 (Vote Underperform)Total Votes: 701MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2018 by MarketBeat.com StaffFeatured Article: What are the Benefits of Index Funds?